Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway

被引:0
|
作者
Lin, Miaomiao [1 ]
Xiao, Yanyi [2 ]
Dai, Yile [2 ]
Mao, Yefan [2 ]
Xu, Liming [2 ]
Zhang, Qiyu [3 ]
Chen, Zhe [3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Key Lab Diag & Treatment Severe Hepatopancreat Di, Zhejiang Prov Top Key Discipline Surg, Wenzhou 325000, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Pancreat Surg, Wenzhou 325000, Zhejiang, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 04期
基金
中国国家自然科学基金;
关键词
Pancreatic ductal adenocarcinoma (PDAC); Epithelial-mesenchymal transition (EMT); Chloroxine; PI3K-AKT-mTOR; MESENCHYMAL TRANSITION;
D O I
10.1007/s12094-023-03328-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPatients with pancreatic cancer have a dismal prognosis due to tumor cell infiltration and metastasis. Many reports have documented that EMT and PI3K-AKT-mTOR axis control pancreatic cancer cell infiltration and metastasis. Chloroxine is an artificially synthesized antibacterial compound that demonstrated anti-pancreatic cancer effects in our previous drug-screening trial. We have explored the impact of chloroxine on pancreatic cancer growth, infiltration, migration, and apoptosis.MethodsThe proliferation of pancreatic cancer cell lines (PCCs) treated with chloroxine was assessed through real-time cell analysis (RTCA), colony formation assay, CCK-8 assay, as well as immunofluorescence. Chloroxine effects on the infiltrative and migratory capacities of PCCs were assessed via Transwell invasion and scratch experiments. To assess the contents of EMT- and apoptosis-associated proteins in tumor cells, we adopted Western immunoblotting as well as immunofluorescence assays, and flow cytometry to determine chloroxine effects on PCCs apoptosis. The in vivo chloroxine antineoplastic effects were explored in nude mice xenografts.ResultsChloroxine repressed pancreatic cancer cell growth, migration, and infiltration in vitro, as well as in vivo, and stimulated apoptosis of the PCCs. Chloroxine appeared to inhibit PCC growth by Ki67 downregulation; this targeted and inhibited aberrant stimulation of the PI3K-AKT-mTOR signaling cascade, triggered apoptosis in PCC via mitochondria-dependent apoptosis, and modulated the EMT to inhibit PCC infiltration and migration.ConclusionsChloroxine targeted and inhibited the PI3K-AKT-mTOR cascade to repress PCCs growth, migration, as well as invasion, and triggered cellular apoptosis. Therefore, chloroxine may constitute a potential antineoplastic drug for the treatment of pancreatic cancer.
引用
收藏
页码:951 / 965
页数:15
相关论文
共 50 条
  • [1] Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway
    Miaomiao Lin
    Yanyi Xiao
    Yile Dai
    Yefan Mao
    Liming Xu
    Qiyu Zhang
    Zhe Chen
    Clinical and Translational Oncology, 2024, 26 : 951 - 965
  • [2] Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway
    Li, Na
    Yang, Fan
    Liu, Dong-Yan
    Guo, Jin-Tao
    Ge, Nan
    Sun, Si-Yu
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (09) : 1164 - 1183
  • [3] Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway
    Na Li
    Fan Yang
    Dong-Yan Liu
    Jin-Tao Guo
    Nan Ge
    Si-Yu Sun
    World Journal of Gastrointestinal Oncology, 2021, (09) : 1164 - 1183
  • [4] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Antonino Glaviano
    Aaron S. C. Foo
    Hiu Y. Lam
    Kenneth C. H. Yap
    William Jacot
    Robert H. Jones
    Huiyan Eng
    Madhumathy G. Nair
    Pooyan Makvandi
    Birgit Geoerger
    Matthew H. Kulke
    Richard D. Baird
    Jyothi S. Prabhu
    Daniela Carbone
    Camilla Pecoraro
    Daniel B. L. Teh
    Gautam Sethi
    Vincenzo Cavalieri
    Kevin H. Lin
    Nathalie R. Javidi-Sharifi
    Eneda Toska
    Matthew S. Davids
    Jennifer R. Brown
    Patrizia Diana
    Justin Stebbing
    David A. Fruman
    Alan P. Kumar
    Molecular Cancer, 22
  • [5] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Glaviano, Antonino
    Foo, Aaron S. C.
    Lam, Hiu Y.
    Yap, Kenneth C. H.
    Jacot, William
    Jones, Robert H.
    Eng, Huiyan
    Nair, Madhumathy G.
    Makvandi, Pooyan
    Geoerger, Birgit
    Kulke, Matthew H.
    Baird, Richard D.
    Prabhu, Jyothi S.
    Carbone, Daniela
    Pecoraro, Camilla
    Teh, Daniel B. L.
    Sethi, Gautam
    Cavalieri, Vincenzo
    Lin, Kevin H.
    Javidi-Sharifi, Nathalie R.
    Toska, Eneda
    Davids, Matthew S.
    Brown, Jennifer R.
    Diana, Patrizia
    Stebbing, Justin
    Fruman, David A.
    Kumar, Alan P.
    MOLECULAR CANCER, 2023, 22 (01)
  • [6] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway
    Du, Liyan
    Li, Xiaomei
    Zhen, Linhong
    Chen, Weiling
    Mu, Lingguang
    Zhang, Yang
    Song, Ailin
    MOLECULAR MEDICINE REPORTS, 2018, 17 (05) : 7163 - 7169
  • [7] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [8] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [9] Genistein inhibits the activation of pancreatic stellate cells by PI3K/AKT/mTOR signaling pathway
    Xue, Ran
    Hao, Jianyu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 44 - 44
  • [10] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70